SkinBioTherapeutics PLC (SBTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SkinBioTherapeutics PLC (SBTX) has a cash flow conversion efficiency ratio of -0.053x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-494.84K ≈ $-60.21 USD) by net assets (GBX9.42 Million ≈ $1.15K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SkinBioTherapeutics PLC balance sheet quality to measure how much of total assets are equity-financed.
SkinBioTherapeutics PLC - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how SkinBioTherapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SkinBioTherapeutics PLC earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
SkinBioTherapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SkinBioTherapeutics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GETT Gold Inc
V:GETT
|
-0.004x |
|
Portmeirion Group PLC
LSE:PMP
|
-0.015x |
|
Haoxi Health Technology Limited Class A Ordinary Shares
NASDAQ:HAO
|
-0.142x |
|
Guess? Inc.
NYSE:GES
|
-0.070x |
|
Actelis Networks Inc.
NASDAQ:ASNS
|
-0.816x |
|
International Zeolite Corp
V:IZ
|
-0.053x |
|
FOXO Technologies Inc.
NYSE MKT:FOXO
|
-0.002x |
|
SysGroup PLC
LSE:SYS
|
-0.014x |
Annual Cash Flow Conversion Efficiency for SkinBioTherapeutics PLC (2016–2025)
The table below shows the annual cash flow conversion efficiency of SkinBioTherapeutics PLC from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see how much is SkinBioTherapeutics PLC worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | GBX9.42 Million ≈ $1.15K |
GBX-1.30 Million ≈ $-157.94 |
-0.138x | +84.99% |
| 2024-06-30 | GBX2.97 Million ≈ $361.35 |
GBX-2.73 Million ≈ $-331.71 |
-0.918x | +30.77% |
| 2023-06-30 | GBX1.99 Million ≈ $242.72 |
GBX-2.65 Million ≈ $-321.84 |
-1.326x | -22.79% |
| 2022-06-30 | GBX2.48 Million ≈ $301.18 |
GBX-2.67 Million ≈ $-325.23 |
-1.080x | -262.16% |
| 2021-06-30 | GBX5.22 Million ≈ $634.55 |
GBX-1.56 Million ≈ $-189.20 |
-0.298x | +17.59% |
| 2020-06-30 | GBX2.47 Million ≈ $300.02 |
GBX-892.14K ≈ $-108.55 |
-0.362x | +3.51% |
| 2019-06-30 | GBX3.81 Million ≈ $463.58 |
GBX-1.43 Million ≈ $-173.82 |
-0.375x | -93.22% |
| 2018-06-30 | GBX3.44 Million ≈ $418.67 |
GBX-667.75K ≈ $-81.25 |
-0.194x | -34.11% |
| 2017-06-30 | GBX4.21 Million ≈ $512.66 |
GBX-609.70K ≈ $-74.18 |
-0.145x | -4733.88% |
| 2016-06-30 | GBX389.85K ≈ $47.43 |
GBX-1.17K ≈ $-0.14 |
-0.003x | -- |
About SkinBioTherapeutics PLC
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the sympt… Read more